Co-Authors
This is a "connection" page, showing publications co-authored by Chien-Yu Cheng and Shu-Hsing Cheng.
Connection Strength
2.427
-
Lopinavir/ritonavir did not shorten the duration of SARS CoV-2 shedding in patients with mild pneumonia in Taiwan. J Microbiol Immunol Infect. 2020 Jun; 53(3):488-492.
Score: 0.875
-
Clinical validation of an automated reverse transcription-insulated isothermal PCR assay for the detection of severe acute respiratory syndrome coronavirus 2. J Microbiol Immunol Infect. 2021 Jun; 54(3):522-526.
Score: 0.232
-
Grazoprevir/elbasvir in peginterferon alfa plus ribavirin experienced patients with chronic genotype 1 HCV/HIV co-infection: a non-randomized, open-label clinical trial. Infect Drug Resist. 2019; 12:937-945.
Score: 0.205
-
Patterns of emergent resistance-associated mutations after initiation of non-nucleoside reverse-transcriptase inhibitor-containing antiretroviral regimens in Taiwan: a multicenter cohort study. Infect Drug Resist. 2018; 11:849-859.
Score: 0.193
-
Multiple types of human papillomavirus infection and anal precancerous lesions in HIV-infected men in Taiwan: a cross-sectional study. BMJ Open. 2018 01 27; 8(1):e019894.
Score: 0.188
-
Author Correction: Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials. Nat Commun. 2021 May 14; 12(1):3001.
Score: 0.059
-
Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials. Nat Commun. 2021 04 15; 12(1):2349.
Score: 0.059
-
Breadth and function of antibody response to acute SARS-CoV-2 infection in humans. PLoS Pathog. 2021 02; 17(2):e1009352.
Score: 0.058
-
Multicenter evaluation of four immunoassays for the performance of early diagnosis of COVID-19 and assessment of antibody responses of patients with pneumonia in Taiwan. J Microbiol Immunol Infect. 2021 Oct; 54(5):816-829.
Score: 0.058
-
A multicenter, randomized, open-label, controlled trial to evaluate the efficacy and tolerability of hydroxychloroquine and a retrospective study in adult patients with mild to moderate coronavirus disease 2019 (COVID-19). PLoS One. 2020; 15(12):e0242763.
Score: 0.057
-
Multicenter evaluation of two chemiluminescence and three lateral flow immunoassays for the diagnosis of COVID-19 and assessment of antibody dynamic responses to SARS-CoV-2 in Taiwan. Emerg Microbes Infect. 2020 Dec; 9(1):2157-2168.
Score: 0.057
-
Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient. Nat Struct Mol Biol. 2020 10; 27(10):950-958.
Score: 0.056
-
Rapid establishment of a COVID-19 biobank in NHRI by National Biobank Consortium of Taiwan. Biomed J. 2020 08; 43(4):314-317.
Score: 0.055
-
A case of transient existence of SARS-CoV-2 RNA in the respiratory tract with the absence of anti-SARS-CoV-2 antibody response. Int J Infect Dis. 2020 Jul; 96:464-466.
Score: 0.055
-
Changing seroprevalence of hepatitis C virus infection among HIV-positive patients in Taiwan. PLoS One. 2018; 13(3):e0194149.
Score: 0.047
-
Evolution of hepatitis A virus seroprevalence among HIV-positive adults in Taiwan. PLoS One. 2017; 12(10):e0186338.
Score: 0.046
-
Trends and outcomes of late initiation of combination antiretroviral therapy driven by late presentation among HIV-positive Taiwanese patients in the era of treatment scale-up. PLoS One. 2017; 12(6):e0179870.
Score: 0.045
-
Multicenter study of skin rashes and hepatotoxicity in antiretroviral-naïve HIV-positive patients receiving non-nucleoside reverse-transcriptase inhibitor plus nucleoside reverse-transcriptase inhibitors in Taiwan. PLoS One. 2017; 12(2):e0171596.
Score: 0.044
-
Skin rash related to once-daily boosted darunavir-containing antiretroviral therapy in HIV-infected Taiwanese: incidence and associated factor. J Infect Chemother. 2014 Aug; 20(8):465-70.
Score: 0.036